Fred Hutchinson Cancer Research Center

GeoVax Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, November 8, 2023
Research, Good manufacturing practice, Vaccine, Treatment, Pfizer, COVID-19, Immunity, Alpha, SARS-CoV-2, Matrix (biology), Biotechnology, Head, HIV, Immune system, Antibody, Cancer, University, Safety, Patient, D, Immunodeficiency, CGMP, Security (finance), Conference, Chronic lymphocytic leukemia, HNSCC, City, Growth, VP40, GeoVax, Patent, FDA, AACR, Protein structure, CLL, MVA, Atrium Health Wake Forest Baptist, Infection, ABL, Fred Hutchinson Cancer Research Center, Pharmaceutical industry, Cryptocurrency, Malaria, Omicron, Moderna

ET

Key Points: 
  • ET
    ATLANTA, GA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a business update.
  • GEO-CM04S1 demonstrated potent antibody and cellular immunity in immunocompromised patients in a recent publication in the journal, Vaccines, in August 2023.
  • Cash Position: GeoVax reported cash balances of $12,687,041 at September 30, 2023, as compared to $27,612,732 at December 31, 2023.
  • ET today, November 8, 2023, to review financial results and provide an update on corporate developments.

Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
FDA, DSM-IV codes, Translation, Fred Hutchinson Cancer Research Center, Infrared spectroscopy correlation table, Bone marrow, University of Washington, Disclosure, Chronic lymphocytic leukemia, Waldenström, Society, PET-CT, Disease, Cancer, Follicular lymphoma, Mustang, University, DL, NHL, Safety, Patient, Investigational New Drug, Associate, American Society of Hematology, HCL, Lymphoma, Pharmaceutical industry, WM

MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”).

Key Points: 
  • MB-106 is being developed in a collaboration between Mustang and Fred Hutchinson Cancer Center (“Fred Hutch”).
  • All patients displayed MB-106 expansion, with peak levels between 7-14 days post-infusion, and CAR-T cell persistence is ongoing at 6 months.
  • From a safety perspective, 3 patients experienced Grade 1 cytokine release syndrome and no occurrences of immune effector cell-associated neurotoxicity syndrome were reported.
  • Dose-limiting toxicities (“DLT”) were monitored through day 28, and no DLTs were observed at DL1.

GeoVax Commences Site Expansion for Phase 2 Trial of Next-Generation COVID-19 Vaccine

Retrieved on: 
Monday, October 30, 2023
Bone marrow, CAR, Immunodeficiency, Fred Hutchinson Cancer Research Center, Biotechnology, Hope, COVID-19 vaccine, City, Pfizer, COVID-19, Cancer, Messenger, GeoVax, University, Atrium Health Wake Forest Baptist, Infection, Safety, Patient, Vaccine, Moderna

ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the Phase 2 clinical trial investigating its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, as a primary vaccine in immunocompromised patients. In addition to study enrollments completed at the City of Hope Medical Center (Duarte, California), the trial will be initiating enrollment of eligible patients at Wake Forest Baptist Medical Center (Winston Salem, North Carolina), the University of Massachusetts Medical Center (Worcester, Massachusetts), and Fred Hutchinson Cancer Research Center (Seattle, Washington).

Key Points: 
  • ATLANTA, GA, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that it has commenced the planned site expansion for the Phase 2 clinical trial investigating its next-generation SARS-CoV-2 vaccine, GEO-CM04S1, as a primary vaccine in immunocompromised patients.
  • Such patients often have difficulty mounting an adequate protective antibody response after receiving currently available COVID-19 vaccines.
  • In the U.S., there are approximately 15 million individuals who, as a result of their compromised immune systems, often do not adequately respond to the current authorized vaccines.
  • These data support the progression of the Phase 2 clinical study, which includes a direct comparison to currently approved mRNA vaccines.

The Galien Foundation Honors 2023 Prix Galien Award Recipients

Retrieved on: 
Friday, October 27, 2023
American Cancer Society, Physiology, Medical genetics, Fred Hutchinson Cancer Research Center, Health technology, P. Roy Vagelos, Peace Corps, Incubator, University of Washington, NASA, Merck, Prix, Creativity, Tufts University School of Medicine, Koch Institute, Endeavour, MIT Jameel Clinic, Digital health, National Aeronautic Association, University, Koch Institute for Integrative Cancer Research, Nobel Prize, Human Genome Sciences, African, ARD International Music Competition, Patient, Doctor of Philosophy, Nursing, Pharmaceutical industry, Biophysics, Biology

NEW YORK, Oct. 27, 2023 /PRNewswire/ -- The Prix Galien USA Committees honored excellence and innovation in life sciences during the Prix Galien USA Forum and 17h annual Prix Galien Awards Gala last night at the American Museum of Natural History in New York City. The USA Committees, composed of 20 committee members, 12 subcommittee members and 20 advisory board members, represented renowned leaders from the biomedical industry and academia. With three Nobel Laureates, these groups honored this year's award winners in the following categories: "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Product for Rare/Orphan Diseases," "Best Medical Technology," "Best Digital Health Solution," "Incubators, Accelerators and Equity" and "Best Startup."

Key Points: 
  • "We are delighted to extend the Prix Galien legacy to another distinguished cohort of winners who have demonstrated the unparalleled skill, innovation, and dedication required across the life sciences industry," said Bruno Cohen, Chairman of The Galien Foundation.
  • "Our Awards Committee, Prix Galien Alumni, and all members of The Galien Foundation extend our gratitude to each winner and nominee, and we look forward to witnessing their impact on the future of global healthcare."
  • The Prix Galien Awards were created in 1970 by Roland Mehl in honor of Galien, the father of medical science and modern pharmacology, to recognize outstanding innovation and scientific advancement.
  • With chapters in 14 countries and Africa, and an inaugural chapter being established in India in 2024, Prix Galien is regarded worldwide as the equivalent of the Nobel Prize for the life science industry.

SciTech Development Announces The Formation of a Distinguished Medical Advisory Board With Top Oncology Specialists

Retrieved on: 
Thursday, October 26, 2023
FAAD, Laboratory, FDA, Columbia University Irving Medical Center, FARMS, SciTech, University of Washington School of Medicine, Duke University, Therapy, SDP, MD, Publication, Retinoid, Duke University School of Medicine, Bone marrow, Fenretinide, Division, Clinical trial, Internal medicine, MAB, Emory University, Malignancy, Bexarotene, University, Immediate, Safety, Cancer, International Society, Patient, Toxicity, Fred Hutchinson Cancer Research Center, Lymphoma, Vaccine, Pharmaceutical industry, Research, Dermatology, Medicine

GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies.

Key Points: 
  • GROSSE POINTE FARMS, Mich., Oct. 26, 2023 /PRNewswire/ -- SciTech Development, LLC, today announced the formation of a distinguished and independent medical advisory board (MAB) comprised of key opinion leaders and world-renowned experts in T-Cell Lymphomas and hematological malignancies.
  • The board will provide strategic and clinical advice for SciTech's outreach and education initiatives within the oncology community.
  • The three medical advisors appointed to the board are Madeleine Duvic, M.D., Larisa Geskin, M.D., and Ajay Gopal, M.D.
  • Madeleine Duvic, MD – "The development of ST-100 is exciting because this new drug holds the promise of improved bioavailability, leading to increased efficacy with low toxicity."

Zymeworks Announces New Director Nominee

Retrieved on: 
Monday, October 16, 2023
Gene expression, Cancer, Internal medicine, Biology, Breast cancer, AACR, Apoptosis, Society, Cyber Security Collaborative Research Alliance, IND, University of Washington Department of Global Health, Fred Hutchinson Cancer Research Center, University, National Cancer Institute, Wellesley College, Disease, Hormone, Johns Hopkins Hospital, American Association for Cancer Research, Johns Hopkins, Harvard Medical School, Publication, Executive, ASCO, Molecular biology, Woman, Patient, Smoking and Health: Report of the Advisory Committee to the Surgeon General of the United States, Pharmaceutical industry, MD, Zymeworks

“With this in mind, we are delighted to invite Dr. Davidson to join our board of directors.

Key Points: 
  • “With this in mind, we are delighted to invite Dr. Davidson to join our board of directors.
  • Her lab studies have paved the way for new clinical trials of drugs that exploit these pathways to kill breast cancer.
  • Prior to joining FHCC, she spent time at the National Cancer Institute, Johns Hopkins in Baltimore and the University of Pittsburgh.
  • Dr. Davidson completed her residency in Internal Medicine at John Hopkins Hospital and a fellowship at the National Cancer Institute.

Mission Bio’s Tapestri Platform Leveraged by Top Academic and Pharma Institutions to Pinpoint Disease-Driving Clones in Multiple Myeloma

Retrieved on: 
Thursday, October 12, 2023
Research, Genetics, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Other Science, Fred Hutchinson Cancer Research Center, Genentech, Erasmus MC, Doctor of Philosophy, Memorial Sloan Kettering Cancer Center, NGS, Multiple myeloma, DNA, Single cell, Bio, SNV calling from NGS data, AML, Flow cytometry, Recurrence, Disease, Exposition, Bone marrow, Acute myeloid leukemia, CNV, Translational medicine, Pharmaceutical industry, Franses Tapestry Archive, MD

This breakthrough data demonstrates the potential for single-cell multi-omics to improve myeloma patient stratification and disease surveillance.

Key Points: 
  • This breakthrough data demonstrates the potential for single-cell multi-omics to improve myeloma patient stratification and disease surveillance.
  • Annually, MM, a blood cancer originating from bone marrow, results in approximately 200,000 new diagnoses globally.
  • Mission Bio's Tapestri Platform is a unique tool that provides detailed information on clonal evolution and potential therapeutic targets at a single-cell level of resolution.
  • The data were presented at the 13th World Clinical Biomarkers & CDx Summit and the 20th International Myeloma Society Annual Meeting and Exposition.

Karius Test® Improves the Diagnosis and Management of Pneumonia in Patients Undergoing Treatment for Blood Cancer

Retrieved on: 
Tuesday, October 10, 2023
Research, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Other Health, Health, Science, Oncology, Diagnosis, Memorial Sloan Kettering Cancer Center, University of Pittsburgh Medical Center, Immunodeficiency, Fred Hutchinson Cancer Research Center, Death, Plasma, DNA, The Study, Risk, National Cancer Institute, Weill Cornell Medicine, University, Loris Karius, MD Anderson Cancer Center, University of Colorado Denver, Principal, University of California, Detection, City, University of Colorado, Bone marrow, Publication, Infection, Bronchoscopy, Duke University Health System, Metagenomics, Patient, Vaccine, Pharmaceutical industry, Pneumonia

“Often clinicians must weigh the risks of invasive procedures in medically fragile patients with an anticipated low diagnostic yield.

Key Points: 
  • “Often clinicians must weigh the risks of invasive procedures in medically fragile patients with an anticipated low diagnostic yield.
  • Identifying the specific cause of pneumonia in patients with blood cancers who are often severely immunocompromised is difficult and critically important to successful treatment.
  • “This well-designed clinical trial conducted at leading academic centers shows that the Karius Test is highly valuable in immunocompromised patients with suspected infection,” said Dr. Ned Sharpless, former Director, National Cancer Institute, and newest Karius board member.
  • “These patients have much to gain through an improved etiologic diagnosis, and the better and more directed treatment of these infections that make this possible,” said Brad Perkins, Chief Medical Officer at Karius.

Roswell Park Cancer Innovation SurVaxM Granted FDA Fast Track Designation

Retrieved on: 
Saturday, October 14, 2023
Multimedia, M&T Bank, Priority review, Cancer, Glomus tumor, Food, Doctor of Philosophy, Hope, Research, Roswell Park Comprehensive Cancer Center, Texas Oncology, Ride, Multiple myeloma, Roswell, MD, Fred Hutchinson Cancer Research Center, National Cancer Institute, University, Survival, Disease, FDA, Glioblastoma, Accelerated approval (FDA), Fast track (FDA), NDA, Neurosurgery, Overlook Medical Center, Northwell Health, Journal, FTD, Fast Track, Assistant, PSA, Regulation of tobacco by the U.S. Food and Drug Administration, American Journal of Clinical Oncology, Principal investigator, Prostate cancer, Brain, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical imaging, Medical device, Online shopping, DRS, Upstate New York, New York University, Roswell Park

BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA). The designation awarded to MimiVax Inc. provides more extensive and accelerated access to FDA resources for the company's development of the novel cancer immunotherapy SurVaxM, which is now in late-stage trials around the country.

Key Points: 
  • The designation awarded to MimiVax Inc. provides more extensive, accelerated access to FDA resources supporting development of SurVaxM, which originated at Roswell Park.
  • BUFFALO, N.Y., Oct. 14, 2023 /PRNewswire-PRWeb/ -- A promising cancer innovation developed at Roswell Park Comprehensive Cancer Center has been granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA).
  • From the world's first chemotherapy research to the PSA prostate cancer biomarker, Roswell Park Comprehensive Cancer Center generates innovations that shape how cancer is detected, treated and prevented worldwide.
  • To learn more about Roswell Park Comprehensive Cancer Center and the Roswell Park Care Network, visit http://www.roswellpark.org , call 1-800-ROSWELL (1-800-767-9355) or email [email protected] .

MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma

Retrieved on: 
Thursday, October 12, 2023
Priority review, Texas Oncology, UCSF, Fred Hutchinson Cancer Research Center, Disease, FDA, Science in newly industrialized countries, Accelerated approval (FDA), NDA, Overlook Medical Center, Journal, Northwell Health, FTD, Fast Track, NYU, American Journal of Clinical Oncology, Roswell Park, Patient, Cleveland Clinic, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical device, Glioblastoma

BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc. , a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).

Key Points: 
  • BUFFALO, N.Y., Oct. 12, 2023 /PRNewswire/ -- MimiVax, Inc. , a biotechnology company focused on the development of glioblastoma vaccine therapy, announced today that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to MimiVax's SurVaxM vaccine being studied for the treatment of newly diagnosed glioblastoma (nGBM).
  • MimiVax Granted Fast Track Designation from FDA for SurVaxM for Newly Diagnosed Glioblastoma.
  • MimiVax is focused on completing the Phase 2b SURVIVE study and securing funding necessary to bring SurVaxM through the FDA approval process.
  • "The receipt of Fast Track Designation affirms the importance of new clinical developments of novel therapies to improve the treatment and outcomes for patients with newly diagnosed glioblastoma," said Michael Ciesielski, CEO of MimiVax.